Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Med-X, Inc. Resumes Equity Crowdfunding, Allows Ordinary Americans To Invest In The Cannabis Industry

Summary

Medical cannabis-focused Med-X, Inc. has resumed its Regulation A+ (Reg A+) equity crowdfunding campaign that stems from the Jobs Act of 2012

Data from Arcview Market Research showed that the legal cannabis industry grew 30% in 2016 in North America alone to reach to $6.7 billion

Med-X is in great position to take advantage of the opportunities in the legal cannabis space

Medical cannabis-focused Med-X, Inc. has resumed its Regulation A+ (Reg A+) equity crowdfunding campaign that stems from the Jobs Act of 2012. New regulations allowing regular Americans to invest in what was once reserved for only the wealthy, is now moving to Main Street.

Over the last year or so, Med-X, Inc. faced a temporary suspension for a late Annual filing from the SEC. Once cleared of the matter, “Med-X management immediately sprang into action to resume Crowdfunding efforts by preparing and filing a Post-Effective Qualification with the SEC”, states Chief Operations Officer Matthew Mills.  On June 30th, 2017, the SEC Re-Qualified Med-X's Offering one again. On September 28th, 2017 Med-X, Inc. re-launched their Crowdfunding efforts.

“We have been Qualified by the SEC and believe we are in full compliance to resume our Regulation A+ crowdfunding efforts once again,” said Mills. He added that “Med-X aims to complete the $14.1 million left from its live offering which is available through StartEngine.com.” The campaign will accept investment starting at $420 which is equivalent to 700 shares of the company.

According to Mills, "Despite the distractions and a scale back this past year, the management team has been diligently working on its business model and continues positioning the Company in accordance with its initial plan of operations. The primary focus will be on the Nature-Cide product line for natural pest control in cannabis cultivation, along with the continued development of the popular online cannabis industry publication, The Marijuana Times".

In March 2017, the Company released the 18-Month Nature-Cide Integrated Pest Management (IPM) for Cannabis Cultivation Report. "The 18-Month report began in 2015 shortly after realizing that the Nature-Cide pesticide products were being recognized by multiple State Agricultural departments, as a product that is approved for use in medical and recreational Marijuana Cultivation”, states Mills.

The Med-X Mission states “We innovate the everyday. The Med-X management team has built a cannabis company that focuses on ancillary products, research and development, and education”.

Legal cannabis showing great investment opportunity

Data from Arcview Market Research showed that the legal cannabis industry grew 30% in 2016 in North America alone to reach to $6.7 billion because of high growth prospects in the U.S. and Canada.

The industry data provider added that based on its projected 25% annual growth rate, the North American sales of marijuana could reach $20.2 billion by 2021. 

Mills explained Med-X is in great position to take advantage of the opportunities in the legal cannabis space. “Due to our management’s hands on background in the fields of medicine, large scale cultivation, commercial pest management as well as operations in internet based wholesale and retail outlets, we feel we have a tremendous advantage, and can use that skill set to climb into a growth position more rapidly than most”.

According to Med-X, Inc. SEC filings, Med-X plans to cultivate and sell high-quality cannabis for the consumer and commercial markets in areas where it is legal and when they are fully licensed to do so.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.